Trials / Completed
CompletedNCT02349295
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 363 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered SC |
| DRUG | Ixekizumab 80 mg Q4W | Administered SC |
| DRUG | Ixekizumab 80 mg Q2W | Administered SC |
Timeline
- Start date
- 2014-12-31
- Primary completion
- 2016-09-09
- Completion
- 2019-06-26
- First posted
- 2015-01-28
- Last updated
- 2020-07-01
- Results posted
- 2017-12-14
Locations
109 sites across 10 countries: United States, Australia, Czechia, France, Germany, Italy, Poland, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02349295. Inclusion in this directory is not an endorsement.